Size | Price | |
---|---|---|
1mg | ||
5mg | ||
10mg | ||
Other Sizes |
Targets |
Integrin αV[1].
|
---|---|
ln Vitro |
Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits PCa cells' adhesion to various extracellular matrix proteins, but not collagen I[1]. Abituzumab (100 µg/mL; 12, 18 h) (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits PCa cells' motility and invasion[1]. in PCa cancer cell lines inhibits integrin-mediated cell signaling for 24 hours (100 µg/mL)[1].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: PCa cells Tested Concentrations: 0.01, 0.1, 1, 10, 30,100 µg/mL Incubation Duration: 24 h Experimental Results: Promoted detachment of PCa cells from vitronectin (up to approximately 20% cells detached at 100 µg/mL), osteopontin (up to approximately 10% cells detached at 100 μg/mL) and fibronectin (up to approximately 10% cells detached at 100 μg/mL) but not from collagen I. Cell Invasion Assay[1] Cell Types: PCa cells Tested Concentrations: 100 µg/mL Incubation Duration: 12, 18 h Experimental Results: Inhibited invasive ability by approximately 25 to 30% compared to vehicle, and inhibited motility by approximately 30 to 40%. Cell Viability Assay[1] Cell Types: PCa, hFOB, Saos2, HS-5, HDMEC cells Tested Concentrations: 0.01, 0.1, 1, 10, 30,100 µg/mL Incubation Duration: 24 h Experimental Results: Inhibited PCa cells adhesion to human osteoblast cell lines hFOB and Saos2 and a bone marrow stromal cell line, HS-5. Promoted detachment of PCa cells from to a known expressor of αv integrins, HDMEC cells. Western Blot Analysis[1] Cell Types: PC3, DU145, C4-2B, LNCaP, ARCaP and VCaP cells Tested Concentrations: 100 µg/mL Incubation Duration: 24 h Experimental Results: Inhibited FAK phosphorylation starting at 12 h and 6 h in C4-2B and LNCaP, respectively; AKT phosphorylation starting at 3 h and 2 h in C4-2B and LNCaP, respectively; and ERK phosphorylation at starting at 1 h and 1.5 h in C4-2B and LNCaP, respectively. |
References |
[1]. Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883.
|
Molecular Weight |
0
|
---|---|
CAS # |
1105038-73-0
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.